DK3277270T3 - Sammensætninger og fremgangsmåder til behandling af anæmi - Google Patents
Sammensætninger og fremgangsmåder til behandling af anæmi Download PDFInfo
- Publication number
- DK3277270T3 DK3277270T3 DK16774184.2T DK16774184T DK3277270T3 DK 3277270 T3 DK3277270 T3 DK 3277270T3 DK 16774184 T DK16774184 T DK 16774184T DK 3277270 T3 DK3277270 T3 DK 3277270T3
- Authority
- DK
- Denmark
- Prior art keywords
- anemia
- procedures
- compositions
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562141420P | 2015-04-01 | 2015-04-01 | |
| US201562270168P | 2015-12-21 | 2015-12-21 | |
| PCT/US2016/025235 WO2016161094A1 (en) | 2015-04-01 | 2016-03-31 | Compositions and methods for treating anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3277270T3 true DK3277270T3 (da) | 2021-12-06 |
Family
ID=57006457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16774184.2T DK3277270T3 (da) | 2015-04-01 | 2016-03-31 | Sammensætninger og fremgangsmåder til behandling af anæmi |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US11324734B2 (da) |
| EP (2) | EP3995138A1 (da) |
| JP (3) | JP6929785B2 (da) |
| KR (2) | KR20240038132A (da) |
| CN (2) | CN107645953B (da) |
| AU (3) | AU2016243700B2 (da) |
| BR (1) | BR112017021097B1 (da) |
| CA (1) | CA2981176A1 (da) |
| CL (2) | CL2017002456A1 (da) |
| CO (1) | CO2017011200A2 (da) |
| CR (2) | CR20170450A (da) |
| CU (1) | CU20170126A7 (da) |
| CY (1) | CY1124869T1 (da) |
| DK (1) | DK3277270T3 (da) |
| EA (1) | EA036920B1 (da) |
| EC (1) | ECSP17073209A (da) |
| ES (1) | ES2900481T3 (da) |
| HK (1) | HK1248590A1 (da) |
| HR (1) | HRP20211862T1 (da) |
| HU (1) | HUE056958T2 (da) |
| IL (3) | IL292262B2 (da) |
| LT (1) | LT3277270T (da) |
| MA (1) | MA41863A (da) |
| MX (3) | MX2017012460A (da) |
| MY (1) | MY192705A (da) |
| NZ (1) | NZ735973A (da) |
| PE (1) | PE20180189A1 (da) |
| PH (1) | PH12017501789A1 (da) |
| PL (1) | PL3277270T3 (da) |
| PT (1) | PT3277270T (da) |
| SA (1) | SA517390054B1 (da) |
| SG (1) | SG11201707994UA (da) |
| SI (1) | SI3277270T1 (da) |
| TW (2) | TWI794725B (da) |
| UA (1) | UA123308C2 (da) |
| WO (1) | WO2016161094A1 (da) |
| ZA (2) | ZA201706681B (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3357911T (lt) | 2006-06-26 | 2022-08-10 | Akebia Therapeutics Inc. | Prolilo hidroksilazės inhibitoriai ir naudojimo būdai |
| NO2686520T3 (da) | 2011-06-06 | 2018-03-17 | ||
| LT3007695T (lt) | 2013-06-13 | 2024-03-25 | Akebia Therapeutics, Inc. | Kompozicijos ir būdai, skirti anemijos gydymui |
| JP2016537365A (ja) | 2013-11-15 | 2016-12-01 | アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用 |
| TW201632504A (zh) | 2015-01-23 | 2016-09-16 | 阿克比治療有限公司 | ２－（５－（３－氟苯基）－３－羥吡啶醯胺基）乙酸之固體形式、其組合物及其用途 |
| CR20170450A (es) * | 2015-04-01 | 2018-04-03 | Akebia Therapeutics Inc | Composiciones y métodos para el tratamiento de la anemia |
| JP6864834B2 (ja) * | 2017-06-14 | 2021-04-28 | ニプロ株式会社 | 投与量決定プログラムおよび投与量決定装置 |
| WO2019028150A1 (en) | 2017-08-01 | 2019-02-07 | Akebia Therapeutics, Inc. | COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES |
| CA3097219A1 (en) | 2018-05-09 | 2019-11-14 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| JP2023501221A (ja) | 2019-10-31 | 2023-01-18 | アケビア セラピューティクス インコーポレイテッド | バダデュスタットを使用する治療方法 |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| AU2021263829A1 (en) * | 2020-04-29 | 2022-12-15 | BioAge Labs, Inc. | Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions |
| JP2023530452A (ja) | 2020-06-19 | 2023-07-18 | アケビア セラピューティクス インコーポレイテッド | バダデュスタットの薬物間相互作用の調節 |
| IL303961A (en) | 2021-01-08 | 2023-08-01 | Akebia Therapeutics Inc | Therapeutic methods using VADADUSTAT |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| WO2022187142A1 (en) | 2021-03-01 | 2022-09-09 | Akebia Therapeutics, Inc. | Modulation of drug-drug interactions of vadadustat |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3655679A (en) | 1969-06-25 | 1972-04-11 | Merck & Co Inc | Certain aryl pyridine carboxylic acid derivatives |
| US3703582A (en) | 1970-04-20 | 1972-11-21 | Merck & Co Inc | Aryl pyridine carboxylic acids in the treatment of inflammation |
| US3894920A (en) | 1971-12-21 | 1975-07-15 | Sagami Chem Res | Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives |
| US4016287A (en) | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
| CA1261335A (en) | 1984-08-29 | 1989-09-26 | Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee | Ethylenediamine monoamide derivatives |
| CN1023479C (zh) | 1985-09-27 | 1994-01-12 | 弗·哈夫曼-拉罗切有限公司 | 乙二胺的单酰胺衍生物的制备方法 |
| TW219933B (da) | 1990-02-26 | 1994-02-01 | Lilly Co Eli | |
| US5405613A (en) | 1991-12-11 | 1995-04-11 | Creative Nutrition Canada Corp. | Vitamin/mineral composition |
| TW352384B (en) | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
| DE4219158A1 (de) | 1992-06-11 | 1993-12-16 | Thomae Gmbh Dr K | Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DK0650961T3 (da) | 1993-11-02 | 1997-09-15 | Hoechst Ag | Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler. |
| ATE149485T1 (de) | 1993-11-02 | 1997-03-15 | Hoechst Ag | Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel |
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| DE4410423A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE4410480A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
| AU5762896A (en) | 1996-04-30 | 1997-11-19 | Hoechst Aktiengesellschaft | 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and the ir use as drugs |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| CN1282319A (zh) | 1997-10-09 | 2001-01-31 | 小野药品工业株式会社 | 氨基丁酸衍生物 |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| JP4495339B2 (ja) | 1998-03-23 | 2010-07-07 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ピペリジニルおよびｎ−アミジノピペリジニル誘導体 |
| US6159379A (en) | 1999-05-04 | 2000-12-12 | Baker Hughes Incorporated | Organic ammonium salts for the removal of water soluble organics in produced water |
| JP2001048786A (ja) | 1999-08-05 | 2001-02-20 | Yamanouchi Pharmaceut Co Ltd | 三環式ヘテロアリール誘導体 |
| AU2001243243B2 (en) | 2000-03-22 | 2004-10-14 | Pharmacia & Upjohn Company | Oxazolidinone tablet formulation |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| JP4590157B2 (ja) | 2001-03-21 | 2010-12-01 | アイシス イノヴェイション リミテッド | アッセイ、方法および手段 |
| SE0101327D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New crystalline forms |
| US6566088B1 (en) | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| WO2003053997A2 (en) | 2001-12-06 | 2003-07-03 | Fibrogen, Inc. | Methods of increasing endogenous erythropoietin (epo) |
| NZ570777A (en) | 2002-05-17 | 2009-04-30 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| CA2495914A1 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| WO2004035812A2 (en) | 2002-10-16 | 2004-04-29 | Isis Innovation Limited | Asparaginyl hydroxylases and modulators thereof |
| AU2003298611A1 (en) | 2002-11-21 | 2004-06-18 | Eli Lilly And Company | Mixed lineage kinase modulators |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| US20060251638A1 (en) | 2003-06-06 | 2006-11-09 | Volkmar Guenzler-Pukall | Cytoprotection through the use of hif hydroxylase inhibitors |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| WO2004108681A1 (en) | 2003-06-06 | 2004-12-16 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| JPWO2005108370A1 (ja) | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| ATE443775T1 (de) | 2004-05-28 | 2009-10-15 | Fibrogen Inc | Hif-prolylhydroxylase-aktivitätstest |
| US20070185116A1 (en) | 2004-05-31 | 2007-08-09 | Tanabe Seiyaku Co., Ltd. | Bicyclic compounds |
| US8013006B2 (en) | 2004-07-14 | 2011-09-06 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| TW200616969A (en) | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
| DE05815688T1 (de) * | 2005-01-27 | 2008-06-26 | Alembic Ltd. | Levetiracetam-formulierung mit verlängerter freisetzung |
| US20080213404A1 (en) | 2005-02-04 | 2008-09-04 | Johnson Randall S | Hif Modulating Compounds and Methods of Use Thereof |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| CA2610956A1 (en) | 2005-06-06 | 2006-12-14 | Fibrogen, Inc. | Improved treatment for anemia using a hif-alpha stabilising agent |
| KR20080028918A (ko) | 2005-06-15 | 2008-04-02 | 피브로겐, 인크. | 암의 치료를 위한 화합물과 방법 |
| WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| US20090176726A1 (en) | 2005-10-11 | 2009-07-09 | Fisher David E | Methods for treating mitf-related disorders |
| EP1960363B1 (en) | 2005-12-09 | 2014-01-22 | Amgen, Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof |
| AU2007205092A1 (en) | 2006-01-09 | 2007-07-19 | Btg International Limited | Modulators of hypoxia inducible factor-1 and related uses |
| EP1983823A1 (en) | 2006-01-17 | 2008-10-29 | VIB vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| JP4801451B2 (ja) | 2006-01-19 | 2011-10-26 | 株式会社日立ハイテクノロジーズ | 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法 |
| CA2635899A1 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| ITMI20060179A1 (it) | 2006-02-02 | 2007-08-03 | Abiogen Pharma Spa | Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse |
| US7625927B2 (en) | 2006-02-27 | 2009-12-01 | Alcon Research, Ltd. | Method of treating glaucoma |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| PE20071020A1 (es) | 2006-03-07 | 2007-12-11 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa |
| ES2288117B1 (es) | 2006-05-08 | 2008-12-01 | Combino Pharm, S.L. | Composicion farmaceutica solida de gabapentina. |
| JP2009537558A (ja) | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
| TWI394747B (zh) | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| LT3357911T (lt) | 2006-06-26 | 2022-08-10 | Akebia Therapeutics Inc. | Prolilo hidroksilazės inhibitoriai ir naudojimo būdai |
| CL2008000066A1 (es) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| CL2008000065A1 (es) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
| JP2008201711A (ja) * | 2007-02-20 | 2008-09-04 | Ss Pharmaceut Co Ltd | システイン臭が低減された固形製剤 |
| WO2008130527A1 (en) | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
| WO2008130508A1 (en) | 2007-04-18 | 2008-10-30 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
| WO2008137060A1 (en) | 2007-05-04 | 2008-11-13 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| WO2008144266A1 (en) | 2007-05-16 | 2008-11-27 | Merck & Co., Inc. | Spiroindalones |
| WO2008141731A2 (en) | 2007-05-18 | 2008-11-27 | Bayer Healthcare Ag | Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| CN101868251B (zh) | 2007-08-06 | 2012-10-10 | 千寿制药株式会社 | 含有HIF-1α和HIF-2α表达抑制物质的药物 |
| TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| KR20100045480A (ko) | 2007-08-10 | 2010-05-03 | 크리스탈지노믹스(주) | 피리딘 유도체 및 이들의 사용방법 |
| WO2009035534A2 (en) | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009043093A1 (en) | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009067790A1 (en) | 2007-11-26 | 2009-06-04 | Uti Limited Partnership | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
| WO2009070644A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| EP2227770A4 (en) | 2007-11-30 | 2011-11-09 | Glaxosmithkline Llc | PROLYLHYDROXYLASEINHIBITOREN |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| EP2240178A4 (en) | 2007-12-19 | 2011-10-26 | Glaxosmithkline Llc | PROLYLHYDROXYLASEHEMMER |
| US20110003013A1 (en) | 2008-01-04 | 2011-01-06 | Garvan Institute Of Medical Research | Method of increasing metabolism |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| DK2268618T3 (da) | 2008-03-03 | 2015-08-17 | Novartis Ag | Forbindelser og sammensætninger som TLR-aktivitetsmodulatorer |
| AU2009273327A1 (en) | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| BRPI0913485A2 (pt) | 2008-09-15 | 2016-06-07 | Kasina Laila Innova Pharmaceuticals Private Ltd | medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres. |
| EP2370422B1 (en) | 2008-11-14 | 2019-06-05 | Fibrogen, Inc. | Thiochromene derivatives as hif hydroxylase inhibitors |
| DK2415771T3 (da) | 2009-03-31 | 2013-10-14 | Kissei Pharmaceutical | Indolizinderivat og anvendelse deraf til medicinske formål |
| AU2010314982B2 (en) | 2009-11-06 | 2013-08-29 | Aerpio Therapeutics Inc. | Compositions and methods for treating colitis |
| JO2978B1 (en) | 2009-12-21 | 2016-03-15 | ايلي ليلي اند كومباني | MGLU2 aids |
| US20140171465A1 (en) | 2011-01-13 | 2014-06-19 | Fibrogen, Inc. | Methods For Increasing Reticulocyte Hemoglobin Content |
| NO2686520T3 (da) | 2011-06-06 | 2018-03-17 | ||
| CN103717214A (zh) | 2011-06-06 | 2014-04-09 | 阿克比治疗有限公司 | 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物 |
| US20130022974A1 (en) | 2011-06-17 | 2013-01-24 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
| AU2012289429B2 (en) | 2011-07-22 | 2016-07-28 | Beijing Betta Pharmaceuticals Co., Ltd | Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
| US20140309256A1 (en) | 2011-11-09 | 2014-10-16 | Fibrogen, Inc. | Therapeutic Method |
| EA201590732A1 (ru) | 2012-11-19 | 2016-01-29 | Азанта А/С | Диспергируемая таблетка |
| KR20160061911A (ko) * | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
| IL298998B1 (en) | 2013-06-06 | 2024-03-01 | Fibrogen Inc | Pharmaceutical formulations of HIF hydroxylase inhibitor |
| LT3007695T (lt) | 2013-06-13 | 2024-03-25 | Akebia Therapeutics, Inc. | Kompozicijos ir būdai, skirti anemijos gydymui |
| MX2016002014A (es) | 2013-08-16 | 2016-07-21 | Ohio State Innovation Foundation | Composiciones y metodos para modular la metilacion de dna. |
| JP2016537365A (ja) | 2013-11-15 | 2016-12-01 | アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用 |
| CA2937349A1 (en) | 2014-01-23 | 2015-07-30 | Akebia Therapeutics, Inc. | Compositions and methods for treating ocular diseases |
| US10617716B2 (en) | 2014-12-16 | 2020-04-14 | Urgo Us, Inc. | Hypochlorous acid formulations and methods for treating skin conditions |
| TW201632504A (zh) | 2015-01-23 | 2016-09-16 | 阿克比治療有限公司 | ２－（５－（３－氟苯基）－３－羥吡啶醯胺基）乙酸之固體形式、其組合物及其用途 |
| US20180065933A1 (en) | 2015-03-20 | 2018-03-08 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| CR20170450A (es) | 2015-04-01 | 2018-04-03 | Akebia Therapeutics Inc | Composiciones y métodos para el tratamiento de la anemia |
-
2016
- 2016-03-31 CR CR20170450A patent/CR20170450A/es unknown
- 2016-03-31 KR KR1020247008210A patent/KR20240038132A/ko active Application Filing
- 2016-03-31 HR HRP20211862TT patent/HRP20211862T1/hr unknown
- 2016-03-31 LT LTEPPCT/US2016/025235T patent/LT3277270T/lt unknown
- 2016-03-31 HU HUE16774184A patent/HUE056958T2/hu unknown
- 2016-03-31 MY MYPI2017703613A patent/MY192705A/en unknown
- 2016-03-31 KR KR1020177031649A patent/KR102647879B1/ko active IP Right Grant
- 2016-03-31 IL IL292262A patent/IL292262B2/en unknown
- 2016-03-31 MX MX2017012460A patent/MX2017012460A/es active IP Right Grant
- 2016-03-31 ES ES16774184T patent/ES2900481T3/es active Active
- 2016-03-31 CR CR20210248A patent/CR20210248A/es unknown
- 2016-03-31 SI SI201631401T patent/SI3277270T1/sl unknown
- 2016-03-31 EA EA201792182A patent/EA036920B1/ru unknown
- 2016-03-31 EP EP21199787.9A patent/EP3995138A1/en active Pending
- 2016-03-31 UA UAA201710516A patent/UA123308C2/uk unknown
- 2016-03-31 PT PT167741842T patent/PT3277270T/pt unknown
- 2016-03-31 DK DK16774184.2T patent/DK3277270T3/da active
- 2016-03-31 SG SG11201707994UA patent/SG11201707994UA/en unknown
- 2016-03-31 PL PL16774184T patent/PL3277270T3/pl unknown
- 2016-03-31 CA CA2981176A patent/CA2981176A1/en active Pending
- 2016-03-31 BR BR112017021097-5A patent/BR112017021097B1/pt active IP Right Grant
- 2016-03-31 MA MA041863A patent/MA41863A/fr unknown
- 2016-03-31 CN CN201680030930.9A patent/CN107645953B/zh active Active
- 2016-03-31 TW TW110101093A patent/TWI794725B/zh active
- 2016-03-31 CN CN202211214971.7A patent/CN115607521A/zh active Pending
- 2016-03-31 WO PCT/US2016/025235 patent/WO2016161094A1/en active Application Filing
- 2016-03-31 NZ NZ735973A patent/NZ735973A/en unknown
- 2016-03-31 EP EP16774184.2A patent/EP3277270B1/en active Active
- 2016-03-31 PE PE2017001640A patent/PE20180189A1/es unknown
- 2016-03-31 CU CUP2017000126A patent/CU20170126A7/xx unknown
- 2016-03-31 AU AU2016243700A patent/AU2016243700B2/en active Active
- 2016-03-31 JP JP2017551039A patent/JP6929785B2/ja active Active
- 2016-03-31 US US15/563,169 patent/US11324734B2/en active Active
- 2016-03-31 MX MX2020009415A patent/MX2020009415A/es unknown
- 2016-03-31 TW TW105110394A patent/TWI718138B/zh active
- 2016-03-31 IL IL305910A patent/IL305910A/en unknown
-
2017
- 2017-09-26 IL IL254710A patent/IL254710B/en unknown
- 2017-09-28 MX MX2021012155A patent/MX2021012155A/es unknown
- 2017-09-28 PH PH12017501789A patent/PH12017501789A1/en unknown
- 2017-09-28 SA SA517390054A patent/SA517390054B1/ar unknown
- 2017-09-29 CL CL2017002456A patent/CL2017002456A1/es unknown
- 2017-10-04 ZA ZA2017/06681A patent/ZA201706681B/en unknown
- 2017-10-31 CO CONC2017/0011200A patent/CO2017011200A2/es unknown
- 2017-11-01 EC ECIEPI201773209A patent/ECSP17073209A/es unknown
-
2018
- 2018-06-29 HK HK18108473.9A patent/HK1248590A1/zh unknown
-
2019
- 2019-07-10 CL CL2019001927A patent/CL2019001927A1/es unknown
-
2020
- 2020-10-02 ZA ZA2020/06107A patent/ZA202006107B/en unknown
- 2020-11-18 AU AU2020273282A patent/AU2020273282B2/en active Active
-
2021
- 2021-08-11 JP JP2021131241A patent/JP7270688B2/ja active Active
- 2021-12-13 CY CY20211101090T patent/CY1124869T1/el unknown
-
2022
- 2022-04-04 US US17/712,709 patent/US11844756B2/en active Active
-
2023
- 2023-01-18 AU AU2023200252A patent/AU2023200252A1/en active Pending
- 2023-04-25 JP JP2023071337A patent/JP2023093684A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3277270T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3495023T3 (da) | Semifluorerede forbindelser og sammensætninger deraf | |
| DK3402499T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes | |
| DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
| DK3377516T3 (da) | Sammensætning til behandling af cancer | |
| DK3212778T3 (da) | Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser | |
| DK3224269T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| DK3600270T3 (da) | Forbindelser og sammensætninger til behandling af hæmatologiske lidelser | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3134130T3 (da) | Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3102555T3 (da) | Sammensætninger af forbindelser og anvendelser deraf | |
| DK3430038T3 (da) | Sammensætninger og fremgangsmåder til cd20-immunterapi | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3137596T3 (da) | Sammensætninger og fremgangsmåder til modulation af komplement faktor b-ekspression | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3081263T3 (da) | Sammensætninger og redskaber til behandling af glaukom | |
| DK3261644T3 (da) | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3319609T3 (da) | Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer | |
| DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne |